Abstract
Cognitive dysfunction is an important focus of research in Parkinson's disease (PD) and Alzheimer's disease (AD). While the concept of amnestic mild cognitive impairment (MCI) as a prodrome to AD has been recognized for many years, the construct of MCI in PD is a relative newcomer with recent development of diagnostic criteria, biomarker research programs and treatment trials. Controversies and challenges, however, regarding PD-MCI's definition, application, heterogeneity and different trajectories have arisen. This review will highlight current research advances and challenges in PD-MCI. Furthermore, lessons from the AD field, which has witnessed an evolution in MCI/AD definitions, relevant advances in biomarker research and development of disease-modifying and targeted therapeutic trials will be discussed.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 425-443 |
| Number of pages | 19 |
| Journal | Neurodegenerative disease management |
| Volume | 5 |
| Issue number | 5 |
| DOIs | |
| State | Published - Oct 1 2015 |
Keywords
- Alzheimer's disease
- Parkinson's disease
- amnestic
- biomarker
- cognitive
- dementia
- diagnostic criteria
- executive function
- mild cognitive impairment
- nonamnestic
ASJC Scopus subject areas
- Medicine(all)